Citi raises the target price for the research company Calliditas to $ 48 per share, from $ 36. It appears from an analysis dated 11 November
Bullish
B
Only US market is 4-5 billion USD, from todays investor presentation.
B
CALT
Hedge Funds Largest Stock Buys
BVF Partners
Bullish
B
Feels prepared to move higher up.
Bullish
B
Latest 13F filings shows
BVF increased to 7,431,562. Holding 14.9%
Bullish
I
Wow...I'm proud to be the first (human) poster on here. No one's looking at this hidden gem of a biotech and it's about to post a Phase III homerun any day now! Phase IIb data for treatment of IgA nephropathy with a special targeted formulation of budesonide (Nefecon®) was reported way back on April 4th, 2015 and achieved highly significant results, so much so that the trial was stopped early in regards to statistical analysis of the primary endpoint! The trial enrolled 150 patients, while Phase III trial has enrolled 200 patients. Patient #200/200 of Phase III trial was last visited October 1st, so data should be out within the next month! 🤞
What did I tell you?! Phase III was a homerun. Congrats to those who held for the Monday news! Of course it sold off, but what an easy 50% profit that was!
Hedge Funds Largest Stock Buys
BVF Partners
BVF increased to
7,431,562. Holding 14.9%
The 200[th] patient’s last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020:
https://www.calliditas.se/en/the-200th-patients-last-visit-completed-in-part-a-of-nefigard-supporting-topline-readout-in-pivotal-phase-3-trial-in-q4-2020-3282/
Pharmalink© (now Calliditas©) announces positive result in Phase 2b Trial of Nefecon®:
https://www.calliditas.se/en/pharmalink-announces-positive-result-in-phase-2b-trial-of-nefecon-2246/